Stocks · News reference
Guggenheim Maintains Buy on Insmed, Lowers Price Target to $205
Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $207 to $205.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 5:04 PM
- Checked
- Aug 7, 2026, 5:04 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Biotech Is Booming, But These 2 Stocks Missed the Memo
The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.
Read original at benzingaJP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175
JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $179 to $175.
Read original at benzingaTruist Securities Reiterates Buy on Insmed, Raises Price Target to $195
Truist Securities analyst Danielle Brill reiterates Insmed (NASDAQ:INSM) with a Buy and raises the price target from $185 to $195.
Read original at benzinga